The ECH1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population originating from HeLa cells, engineered to disrupt the ECH1 gene encoding mitochondrial enoyl-CoA hydratase and isomerase. This loss-of-function model serves as a powerful tool for dissecting the roles of fatty acid beta-oxidation and unsaturated fatty acid metabolism in human cellular contexts. The knockout cell pool is generated by CRISPR/Cas9-mediated gene disruption, providing a heterogeneous population suitable for pooled functional screens and bulk biochemical analyses.
HeLa cells are an immortalized human cervical epithelial cell line derived from a cervical adenocarcinoma, widely employed as a versatile host for gene editing due to their robust growth characteristics, ease of transfection, and extensive background in cancer biology and metabolic research. As a standard model, HeLa cells enable the study of metabolic pathways in a well-characterized system, allowing researchers to directly assess the impact of ECH1 loss on mitochondrial function and lipid handling.
ECH1 encodes an enoyl-CoA hydratase/isomerase that catalyzes the hydration of 2-trans-enoyl-CoA to 3-hydroxyacyl-CoA, a critical step in mitochondrial fatty acid beta-oxidation, and also isomerizes 3-cis and 3-trans double bonds in unsaturated fatty acid intermediates. ECH1 functions downstream of the carnitine palmitoyltransferase system and acyl-CoA dehydrogenases such as ACADVL, and its activity is essential for channeling fatty acid-derived carbons into the TCA cycle and oxidative phosphorylation, producing NADH, FADH2, and ATP. The enzyme is transcriptionally regulated by PPAR??, PGC-1??, and ERR??, and its function is integrated with the mitochondrial trifunctional protein complex (HADHA/HADHB) and electron transfer flavoproteins. Disruption of ECH1 thereby abolishes its hydratase and isomerase activities, impairing the processing of unsaturated fatty acids and leading to reduced acetyl-CoA generation and energy production.
In the HeLa carcinoma background, ECH1 knockout accentuates metabolic vulnerabilities, as cancer cells often rely on lipid catabolism for energy and biosynthesis. This model enables the investigation of how mitochondrial fatty acid oxidation defects intersect with oncogenic metabolism, including shifts to glycolytic reliance and altered redox balance. By eliminating ECH1 function, researchers can assess compensatory pathways, such as peroxisomal oxidation, and link metabolic dysregulation to hallmarks like apoptosis resistance and oxidative stress.
Typical applications encompass metabolic flux analysis using Seahorse assays to measure oxygen consumption rates, fatty acid oxidation assays tracking radiolabeled or fluorescent substrates, ATP quantification to gauge energy homeostasis, and lipidomic profiling to characterize accumulated intermediates. Additionally, the cells are suited for screening metabolic modulators, assessing mitochondrial dysfunction via ROS and membrane potential measurements, and validating downstream signaling effects through western blotting and RT-qPCR. This polyclonal knockout population offers a robust platform for both targeted studies and high-throughput approaches, facilitating advances in mitochondrial disease research, cancer metabolism, and drug discovery. For further details or to discuss customized applications, please contact Ascent Research.
